30 closest matches · ranked by relevance
Hypersensitivity
Primary: The Percentage of Participants With Adjudicated Hypersensitivity Signs/Symptoms, for Each Sugammadex Dose Group and Placebo. — 0.7; 4.7; 0 percentage of participants
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
History of IgE Dependent Reaction to a Penicillin Product
Primary: Negative Predictive Value — 98.0 percentage of participants
Anatomic Stage 0 Breast Cancer AJCC v8 · Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8
Primary: Proportion of Patients With Grade 2 or Greater Reactions That Require Parenteral Rescue Medications to Treat an Infusion Hypersensitivity Reaction (HSR) After the First…
Epilepsies, Partial
Primary: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert — 27 participants
Acute Urticaria
Primary: Change of Patient Rated Pruritus Score — -1.61; -1.50 score on a scale
Acute Urticaria
Primary: Extent of Urticaria/Erythema Score (Physician Assessment) — 1.91; 1.74; 1.53; 1.12 units on a scale
Allergic Contact Dermatitis
Primary: Number of Participants With Positive Reactions to Ethylenediamine Dihydrochloride in MC (Methylcellulose) and Ethylenediamine Dihydrochloride in PVP…
Acute Kidney Injury
Primary: Percentage of Patients With Progression of AKI OR Dialysis OR Death — 639; 585 Participants
Hymenoptera Venom Allergy · Antihypertensive Treatment
Primary: Frequency of Side Effects (=Systemic Reaction, SR) During Venom Immunotherapy (VIT) — 19; 74 Participants — p=0.25
Contact Dermatitis
Primary: Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21 — 78.9 percentage of concordant responses
Healthy
Primary: Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration — 4.79; 12.83; 11.08; 12.17 units on a scale
HIV-1 Infection
Primary: Number of Participants Who Reported Unlisted Adverse Drug Reaction. — 0 participants
Contact Dermatitis
Primary: Diagnostic Performance: Optimal Test Allergen Concentration — 38.1; 47.6; 52.4; 30.8 percentage of participants
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
Allergic Skin Reaction
Primary: Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) — 0 participants
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
Cocaine Dependence · Opioid Dependence
Primary: Urine Toxicology for Cocaine. — 84; 68; 56; 67 % cocaine + urines over 2 week blocks
Kidney Transplantation
Primary: Tacrolimus Bioavailability (F) — 0.224; 0.681 ratio of oral to IV — p=0.006
Diabetes Mellitus, Type 1
Primary: The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment. — 642; 430; 27.4; 17.9 pg/mL
Systemic Lupus Erythematosus (SLE) · Juvenile SLE · Cutaneous Lupus
Primary: Serum Levels of Thalidomide — 415.1 ng/mL
Latent Tuberculosis · Human Immunodeficiency Virus · Rifamycins Causing Adverse Effects in Therapeutic Use
Primary: Doravirine Maximum Concentration (Cmax) — 1.7; 1.3 ug/mL
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants
Eosinophilia · Hypereosinophilic Syndrome · Leukocyte Disorder
Primary: Mean Percent Change in Eosinophil Count After Glucocorticoid Challenge — -69.6; -13.6 percentage of eosinophil count